Testing Fosmanogepix for Serious Mold Infections
Treatments studied
Part of Infections clinical trials.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious mold infection (like Aspergillus, Fusarium, or Mucorales) confirmed by a doctor.
- The infection should not be controlled by standard treatments or be caused by a mold that is resistant to many drugs.
- You should not have chronic lung conditions like aspergillosis or a fungus ball in the lung.
- You cannot be on dialysis or need it soon.
- You must be able to care for yourself for most daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
This program provides access to an experimental antifungal drug called fosmanogepix for people with serious or life-threatening fungal infections that haven't responded to other treatments. It's for those who have no other options left.
This study tests a new imaging agent that may help doctors see mold infections in the body. It involves healthy volunteers and people with mold infections, and aims to improve how these infections are detected and monitored.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
This study uses noninvasive breathing/relates imaging (MRI or CT) to help diagnose mold infections in the lungs in children and young adults. It may help doctors find these infections sooner, especially in people with weakened immune systems.
Hear when a new Invasive Mold Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.